Clopidogrel: a pharmacoeconomic review

References

• World Health Organization. The world health report 2004 – changing history. World Health Organization;, Geneva 2004
   Google Scholar
• Drouet L. Atherothrombosis as a systemic disease. Cerebrovascular Diseases 2002; 13 (Suppl.): 1: 1–16
   PubMedGoogle Scholar
• Herbrt J-M, Savi P, Maffrand J-P. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. European Heart Journal 1999; 1((Suppl. A)) A31–A40
   Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis 2000; 84: 891–896
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with ACS without ST-segment elevation. New England Journal of Medicine 2001; 345: 494–502
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–533
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Journal of the American Medical Association 2002; 288: 2411–2420
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New England Journal of Medicine 2005; 352: 1179–1189
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. Journal of the American Medical Association 2005; 294: 1224–1232
   PubMed Web of Science ®Google Scholar
• COMMITT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607–1621
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348((9038):)1329–1339
   PubMedGoogle Scholar
• Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine 2006; 354: 1706–1717
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, et al. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology 2007; 49: 1982–1988
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Journal of the American College Cardiology 2007; 50: e1–e157
   Google Scholar
• Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Journal of the American College Cardiology 2004; 44: E1–E211
   PubMedGoogle Scholar
• Smith SC, Jr, Feldman TE, Hirshfeld JW, Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Journal of the American College Cardiology 2006; 47: e1–e121
   Google Scholar
• Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal 2002; 23: 1809–1840
   PubMed Web of Science ®Google Scholar
• William Weintraub. Cardiovascular Health Economics. Humana Press, NJ 2003
   Google Scholar
• Sonnenberg FA, Beck R. Markov models in medical decision making: a practical guide. Medical Decision Making 1993; 13(4): 322–338
   Web of Science ®Google Scholar
• Lamy A, Jonsson B, Weintraub WS, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. European Journal of Cardiovascular Prevention and Rehabilitation 2004; 11(6): 460–465
   Google Scholar
• Annemans L, Lindgren P, Frei A, et al. Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries Analysis (abstract). European Heart Journal 2003; 24 (Suppl.):: 3002
   Google Scholar
• Lindgren P, Jonsson B, Spiesser J, et al. Short and long term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST-segment elevation (ACS) in scandinavian countries (abstract). Value in Health 2003; 6: 621
   Web of Science ®Google Scholar
• Pietrasik A, Niewada M, Spiesser J, et al. The cost-effectiveness of clopidogrel acute coronary syndrome without ST-segment elevation in Poland (abstract). Value in Health 2004; 7: 687
   Web of Science ®Google Scholar
• Belousov YB, Lazebnik LB, Bykov AV, et al. Economic analysis of the use of clopidogrel in patients with acute coronary syndrome without ST-segment elevation from the Russian health care system perspective (abstract no. PCV52). Value in Health 2003; 6: 663
   Web of Science ®Google Scholar
• Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. Journal of the American College of Cardiology 2005; 45: 838–845
   PubMed Web of Science ®Google Scholar
• Lindgren P,, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel acute coronary syndrome in sweden: a long term model based on the cure trial. Journal of Internal Medicine 2004; 255: 562–570
   PubMed Web of Science ®Google Scholar
• Schwartz B, Lindgren P, Nanz S. Long-term cost-effectiveness of clopidogrel plus acetylsalicylic acid in patients with acute coronary syndrome without ST-segment elevation in Austria. PharmacoEconomics-German Research Articles 2004; 2: 31–41
   Google Scholar
• Badia X, Bueno H, Gonzalez JR, et al. Short and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy acute coronary syndrome patients in Spain. Revista Espanola de Cardiologia 2005; 58: 1385–1395
   PubMed Web of Science ®Google Scholar
• Bruggenjurgen B, Lindgren P, Ehlken B. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. European Journal of Health Economics 2007; 8: 51–57
   PubMed Web of Science ®Google Scholar
• Van Hout BA, Tangelder MJD, Berovoets P, et al. Cost-effectiveness analysis of clopidogrel in acute coronary syndromes witout ST-segment elevation in the Netherlands (abstract). Value in Health 2003; 6: 667–668
   Web of Science ®Google Scholar
• Mehta SR, Weintraub WS, Jonsson B, et al. Incremental cost-effectiveness of early and long term clopidogrel in patients undergoing PCI in the CURE trial: the PCI-CURE economic analysis (abstract). Journal of the American College of Cardiology 2003; 41((Suppl. 2))383A, (Plus poster presented at 52nd annual ACC meeting)
   Google Scholar
• Spiesser J, Carita P, Annemans L, et al. Economic impact of clopidogrel in patients with acute coronary syndromes without ST-segment elevation (ACS) undergoing Percutaneous coronary interventions (PCI): a European review (abstract). Value in Health 2003; 6: 651
   Web of Science ®Google Scholar
• Annemans L, Lindgren P, Frei A, et al. Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing Percutaneous coronary interventions: a five European countries analysis (abstract). European Heart Journal 2003; 24((Suppl)) 130
   PubMedGoogle Scholar
• Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to one year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. American Heart Journal 2006; 151: 219–227
   PubMed Web of Science ®Google Scholar
• Lindgren P, Stenestrand U, Malmberg K, et al. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clinical Therapeutics 2005; 27: 100–110
   PubMed Web of Science ®Google Scholar
• Beinart SC, Kolm P, Veledar E, et al. Long-term cost-effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology 2005; 46: 761–769
   PubMed Web of Science ®Google Scholar
• Cowper PA, Udayakumar K, Sketch MH, Jr, Peterson ED. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. Journal of the American College of Cardiology 2005; 45: 369–376
   PubMed Web of Science ®Google Scholar
• Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention. European Journal of Health Economics 2006; 6: 354–362
   Google Scholar
• Schleintz M, Weiss P, Owens D, et al. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: A cost-effectiveness analysis. American Journal of Medicine 2004; 116: 797–806
   PubMed Web of Science ®Google Scholar
• Haldemann R, Lüscher TF, Szucs TD. Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a costeffectiveness analysis based on the CAPRIE study. Schweitzer Rundsch Med Prax 2001; 90: 539–545
   PubMedGoogle Scholar
• Annemans L, Lamotte M, Levy E, et al. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on CAPRIE trial. Journal of Medical Economics 2003; 6: 55–68
   Google Scholar
• Van Hout BA, Tangelder MJD, Bervoets P, et al. Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke and peripheral arterial disease in the Netherlands (abstract). Value in Health 2003; 6: PCV27
   Web of Science ®Google Scholar
• Gaspoz JM, Coxson PG, Goldman PA, et al. Cost-effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. New England Journal of Medicine 2002; 346: 1800–1806
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kolm P, Spiesser J, et al. Cost-effectiveness of clopidogrel in patients with ST-segment elevation myocardial infarction. Circulation 2006; 114((18))II–827
   Google Scholar
• Berg J, Lindgren P, Spiesser J, et al. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: A European model based on the CLARITY and COMMIT trials. Clinical Therapeutics 2007; 29: 1184–1202
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of smoking cessation program after myocardial infarction. Journal of the American College of Cardiology 1993; 22: 1697–1702
   PubMed Web of Science ®Google Scholar
• Franzosi MG, Maggioni AP, Santoro E, et al. Cost-effectiveness analysis of early lisinopril use in patient with acute myocardial infarction. Results from GISSI-3 trial. Pharmacoeconomics 1998; 13: 337–346
   PubMed Web of Science ®Google Scholar
• Briggs A, Mihaylova B, Sculpher M. Cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 2007; 93: 1081–1086
   PubMed Web of Science ®Google Scholar
• Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. Journal of the American Association of Medicine 2000; 284: 2748–2754
   PubMed Web of Science ®Google Scholar
• Johannesson M, Jonsson B, Kjekshus J, et al. Cost-effectiveness of simvastatin treatment to lower cholesterol level in patients with coronary Heart disease. Scandanavian Simvastatin Survival Study Group. New England Journal of Medicine 1997; 336: 332–336
   PubMed Web of Science ®Google Scholar
• Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol level. American Heart Journal 2001; 141: 727–734
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. Journal of the American Association of Medicine 2002; 288: 1851–1858
   PubMed Web of Science ®Google Scholar
• Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectivness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patient with non-ST-elevation acute coronary syndromes. Circulation 2000; 101: 366–371
   PubMed Web of Science ®Google Scholar
• Mark DB, Hlatky MA, Calliff RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New England Journal of Medicine 1995; 332: 1418–1424
   PubMed Web of Science ®Google Scholar